XML 47 R34.htm IDEA: XBRL DOCUMENT v3.19.1
Collaboration and License Agreements (Details)
$ in Thousands, € in Millions
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Feb. 28, 2019
USD ($)
Nov. 30, 2017
USD ($)
Oct. 31, 2017
USD ($)
Nov. 30, 2015
USD ($)
Mar. 31, 2015
USD ($)
Oct. 31, 2014
USD ($)
Oct. 31, 2014
EUR (€)
Mar. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Mar. 31, 2018
USD ($)
Sep. 30, 2016
USD ($)
Sep. 30, 2016
USD ($)
Dec. 31, 2015
USD ($)
Dec. 31, 2014
USD ($)
Collaboration and License Agreements [Abstract]                            
Sanofi Upfront Payment       $ 300,000                    
Sanofi Development Milestones       110,000                    
Sanofi Regulatory Milestones       220,000                    
Sanofi Outcomes Study Milestone       100,000                    
Sanofi Sales Milestone Payments       990,000                    
Sanofi Commercialization Costs Funded by Lexicon Maximum Amount       100,000                    
Sanofi Revenue Allocated to License Deliverable       126,800                    
Sanofi Revenue Allocated to Development Deliverable       113,800                    
Sanofi Revenue Allocated to Funding Deliverable       $ 59,400                    
Sanofi Revenue Recognized               $ 100   $ 19,300        
Ipsen Total Payments               47,200            
Ipsen Maximum Regulatory And Commercial Milestones               9,600            
Ipsen Maximum Sales Milestones | €             € 72              
Ipsen Total Upfront Payments         $ 24,500                  
Ipsen Milestone Payment                   5,100 $ 6,400 $ 6,400    
Ipsen Milestone Payment Received $ 2,250 $ 3,840 $ 3,840           $ 1,250 5,100        
Ipsen Revenue Allocated to License Deliverable                         $ 1,400 $ 21,200
Ipsen Revenue Allocated to Development Deliverable           $ 1,700                
Ipsen Revenue Allocated to Committee Deliverable           $ 100                
Ipsen Revenue Recognized               $ 2,300   $ 300